BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the ind

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewe

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in mi

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analy

The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hoste

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight a

U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining

Activist investor DOMA nominates three directors to Pacira's board, citing weak oversight, misse

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the L

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term

Pacira BioSciences (NASDAQ:PCRX) sees FY2026 sales of $745.000 million-$770.000 million vs $790.214

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the ana

-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioi

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintain

Barclays analyst Glen Santangelo initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Eq

-- New data published in Pain Physician shows significant improvement in functional outcomes with io

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

HC Wainwright & Co. analyst Douglas Tsao assumes Pacira BioSciences (NASDAQ:PCRX) with a Buy

Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and

Pacira BioSciences (NASDAQ:PCRX) lowers FY2025 sales outlook from $730.000 million-$750.000 million

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.70 per share which beat the analy

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

  On Thursday, 369 companies hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  During Thursday's session, 406 companies made new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.